Noritomo Shimada
Overview
Explore the profile of Noritomo Shimada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
144
Citations
1734
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, et al.
Int J Cancer
. 2023 Nov;
154(6):1043-1056.
PMID: 37994647
Atezolizumab plus bevacizumab (AB) and lenvatinib can be alternatively used as first-line systemic treatment of unresectable hepatocellular carcinoma (HCC). However, no direct comparison of the two regimens has been performed...
12.
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, et al.
Cancer Med
. 2023 Nov;
12(24):21680-21693.
PMID: 37987139
Aim: This retrospective study compared the impact of atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib (LEN) on the liver function in patients with hepatocellular carcinoma. Methods: We included 526 patients who...
13.
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, et al.
Hepatol Res
. 2023 Nov;
54(4):382-391.
PMID: 37983642
Aim: Elderly patients are believed to have a reduced immune capacity, which may make immunotherapy less effective. The aim of this study was to compare the therapeutic outcome of atezolizumab...
14.
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, et al.
Liver Int
. 2023 Oct;
44(1):113-124.
PMID: 37789669
Background & Aims: The study goal was to compare the outcomes of patients with intermediate-stage (Barcelona Clinic Liver Cancer [BCLC]-B) hepatocellular carcinoma (HCC) who received atezolizumab plus bevacizumab (Atezo/Bev) or...
15.
Tanaka K, Tsuji K, Hiraoka A, Tada T, Hirooka M, Kariyama K, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686624
Aim: This study aimed to evaluate the ability of a previously reported tumor marker (TM) score involving alpha-fetoprotein (AFP), fucosylated AFP (AFP-L3), and des gamma-carboxy prothrombin (DCP) as TMs in...
16.
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, et al.
Liver Cancer
. 2023 Aug;
12(3):209-217.
PMID: 37601983
Background/aim: There is no known report regarding the relationship of atezolizumab plus bevacizumab (Atez/Bev) treatment with muscle volume loss (MVL) in unresectable hepatocellular carcinoma (u-HCC) patients. This study aimed to...
17.
Nouso K, Shiota S, Fujita R, Wakuta A, Kariyama K, Hiraoka A, et al.
Cancer Med
. 2023 Aug;
12(17):17849-17855.
PMID: 37563961
Aim: Multiple studies have revealed the correlation between gut microbiome and the response to checkpoint inhibitors (CPIs) in patients with cancer, and oral administration of butyrate-producing enterobacteria has been reported...
18.
Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, et al.
Oncology
. 2023 Aug;
101(9):542-552.
PMID: 37552968
Introduction: Systemic treatment is generally recommended for Child-Pugh (CP) A status patients with an unresectable hepatocellular carcinoma (uHCC). This study aimed to elucidate differences regarding therapeutic efficacy between lenvatinib (LEN),...
19.
Tada F, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, et al.
J Gastroenterol
. 2023 Aug;
58(11):1134-1143.
PMID: 37528255
Background: Bevacizumab inhibits vascular endothelial growth factor-A (VEGF-A), though is known to increase bleeding risk as an adverse event (AE). This study examined whether atezolizumab/bevacizumab (Atez/Bev) for unresectable hepatocellular carcinoma...
20.
Toyoda H, Kanneganti M, Melendez-Torres J, Parikh N, Jalal P, Pinero F, et al.
Clin Gastroenterol Hepatol
. 2023 Jul;
22(1):72-80.e4.
PMID: 37442316
Background & Aims: Widespread use of direct-acting antivirals for hepatitis C virus infection has been paralleled with increased numbers of patients with hepatocellular carcinoma (HCC) after achieving sustained virologic response...